Cargando…

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study

This study assessed the trends in methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine–cisplatin (GC) regimens in Korean patients with metastatic urothelial carcinoma (UC) and compared the side effects and overall survival (OS) rates of the two regimens using nationwide popul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yong Seong, Ha, Moon Soo, Tae, Jong Hyun, Chang, In Ho, Kim, Tae-Hyoung, Myung, Soon Chul, Nguyen, Tuan Thanh, Kim, Myoungsuk, Lee, Kyung-Eun, Kim, Yuwon, Woo, Hyun-ki, Kyoung, Dae-Sung, Kim, Hasung, Choi, Se Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988935/ https://www.ncbi.nlm.nih.gov/pubmed/36879015 http://dx.doi.org/10.1038/s41598-023-30356-x

Ejemplares similares

Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study
por: Tae, Jong Hyun, et al.
Publicado: (2022)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
por: Kim, Ki Hong, et al.
Publicado: (2015)

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
por: Chung, Doo Yong, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials
por: Lee, Yong Seong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
por: Woo, Sang Myung, et al.
Publicado: (2017)

Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
por: You, Min su, et al.
Publicado: (2019)

Changes in patient perceptions regarding ChatGPT-written explanations on lifestyle modifications for preventing urolithiasis recurrence
por: Kim, Seong Hwan, et al.
Publicado: (2023)

Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study
por: Kim, Tae-Hwan, et al.
Publicado: (2022)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
por: Pattarawat, Pawat, et al.
Publicado: (2020)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

Urinary tract infection after radiation therapy or radical prostatectomy on the prognosis of patients with prostate cancer: a population-based study
por: Hyun, Jihye, et al.
Publicado: (2023)

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
por: Pfister, Christian, et al.
Publicado: (2020)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Risk of Suicide Attempt after Thyroidectomy: A Nationwide Population Study in South Korea
por: Kim, Hyewon, et al.
Publicado: (2021)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
por: Abida, Wassim, et al.
Publicado: (2016)

Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma
por: Cho, Seulki, et al.
Publicado: (2017)

The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study
por: Park, Jiyun, et al.
Publicado: (2022)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma
por: Kim, Guen Tae, et al.
Publicado: (2022)

Gemcitabine maintenance versus observation after first-line chemotherapy in patients with metastatic urothelial carcinoma: a retrospective study
por: Kim, Hyunho, et al.
Publicado: (2020)

PLAG alleviates cisplatin-induced cachexia in lung cancer implanted mice
por: Kim, Guen Tae, et al.
Publicado: (2022)

Risk of epilepsy in gonadal teratoma: a nationwide population-based study
por: Kim, Seonghoon, et al.
Publicado: (2023)

Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer
por: Lee, Yun-Gyoo, et al.
Publicado: (2015)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
por: Cheon, Jaekyung, et al.
Publicado: (2021)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5erakpbpb1fsedpjvohpeifd9q